The following are the active pre-clinical and clinical stage development programs at Enterin, as of October 3, 2022.
Enterin has an innovative discovery engine with several exciting molecules at different stages of development. Our molecules are synthetic derivatives of either shark or mammalian aminosterols. Our lead molecule, ENT-01, is being advanced through clinical development for the treatment of Parkinson’s Disease and other potential neurodegenerative diseases. Currently, we are investigating the benefit of ENT-01 in the treatment of various non-motor symptoms of Parkinson’s Disease, including psychosis (hallucinations), dementia, and potentially constipation, and also in the treatment of autism.
Learn more about our lead programs.
ENT-01 (Oral)
PD + Constipation
Phase 2b (complete)
ENT-01 (Oral)
PD + Psychosis
Phase 2a (2023 start)
ENT-01 (Oral)
PD + Dementia
Phase 2a (2023 start)
ENT-01 (Oral)
Autism
Evaluating for Phase 2
ENT-03 (Subcutaneous)
Obesity/T2D
Phase 1 (2023 start)
ENT-03 (Subcutaneous)
Alzheimer’s Disease
Phase 2 (after Phase 1)
ENT-05 (Oral)
Undisclosed
Pre-Clinical